SUPT20H

Across TCGA pan-cancer cohorts, SUPT20H Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SUPT20H data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SUPT20H Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SUPT20H expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, CHOL, and BRCA are the cancer types where SUPT20H Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.442	.027	16	view →
CHOL	DFS	Median	All	0.121	0.495	.024	6	view →
BRCA	DFS	Median	II,III,IV	0.358	0.889	.011	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	6	view →
SKCM	OS	Median	All	0.275	0.784	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.242	0.613	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SUPT20H–UCEC (DFS)

Open the UCEC breakdown →